Aurora Cannabis (TSX:ACB): Why You Should Buy the After-Earnings Dip

Despite failing to deliver results on par with analysts estimates, here is why Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) is still an interesting option.

| More on:
Going against the grain

Image source: Getty Images

It is always a crucial time when one of the top cannabis companies releases its earnings report. Given the nascent nature of the industry, the performance of these firms gives us important clues as to how the market is evolving.

Aurora Cannabis (TSX:ACB)(NYSE:ACB) is the latest top pot company to release its financial results.

Let’s see how Aurora performed.

Before a fall…

As the old proverb goes, pride comes before a fall. That is perhaps what happened to Aurora Cannabis during the last quarter.

Just about a month ago, the Edmonton-based marijuana company predicted it would post revenues in the neighborhood of $100 million to $107 million. The consensus analyst estimates also projected that Aurora’s revenues would break the $100 million mark, placing them at around $108 million for the quarter.

However, the company failed to deliver on its promise and failed to live up to analysts estimates. Aurora’s revenues “only” came in at $98.9 million. As a result, the firm’s share price dropped sharply during the after-hour trading session following its earnings release. 

Although holding Aurora accountable for its miss is important, it is equally essential to focus on the big picture. All things considered, the marijuana company’s revenues weren’t bad at all. After all, the $98.9 million figure represented a 415% increase year over year, and, more importantly, a 52% sequential increase.

Note that Aurora’s biggest rival in the Canadian market — Canopy Growth — failed to deliver a sequential revenue increase during its last quarter.

As the Canadian market tightens, it is becoming harder for cannabis firms to acquire and maintain a notable share of the market. Aurora, though, managed to deliver serious organic growth in this competitive environment. 

Further, the company’s medical segment seems to be firing on all cylinders. Aurora’s average net selling price for recreational product fell by about 6%, but its average retail price for medical products remained constant. There is bound to be a supply glut in the recreational market eventually, which will drag down prices and margins.

Fortunately, Canadian cannabis companies are anxiously awaiting the launch of the derivative market. Thus, although the lion’s share of Aurora’s revenues came from its recreational segment, that shouldn’t be cause for concern.

Finally, the company continues to increase its production capacity. During the quarter, Aurora added several new cultivation facilities, which led to an 86% sequential increase in production volume. 

The bottom line

Aurora has more tricks up its sleeve. The company recently made an acquisition that will improve its standing in the lucrative CBD market. All these developments should help the firm maintain strong top line growth.

Lastly, I still believe Aurora will eventually find a partner with deep pockets that will further improve its prospects. All these factors make Aurora one of the better plays in the cannabis market, in my opinion. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Prosper Junior Bakiny owns shares of Aurora Cannabis. 

More on Cannabis Stocks

Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.
Cannabis Stocks

Canopy Growth: Is There Budding Potential in the Cannabis Market?

Canopy Growth stock hit 52-week lows recently on news of needing to re-file on its BIoSteel business, so what now?

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

What’s Happening With Cannabis Stocks in May 2023?

Cannabis stocks were up this week, as the market began to turn, but how long will it last, and is…

Read more »

Cannabis smoke
Cannabis Stocks

Are Cannabis Stocks a Good Buy in May 2023?

If you're going to buy cannabis stocks, these are pretty much the only two I would consider. Even so, you…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Aurora Cannabis: Time to Light Up Your Portfolio?

Here's my take on whether Aurora Cannabis (TSX:ACB) is worth adding to a growth portfolio right now, given its growth…

Read more »

Target. Stand out from the crowd
Tech Stocks

These Undervalued TSX Stocks Are a Bargain in May 2023

If you're willing to bet on a rebound, these are the three TSX stocks I would consider first as they…

Read more »

A cannabis plant grows.
Cannabis Stocks

Tilray Stock Is Scraping 52-Week Lows: Will it Bottom Out Soon?

Tilray (TSX:TLRY) stock remains down 53% in the last year, but when will this company hit the bottom and start…

Read more »

Medicinal research is conducted on cannabis.
Metals and Mining Stocks

2 Canadian Stocks That Are Simply Too Cheap to Avoid

These two Canadian stocks have sunk lower and lower, which is why now could be the right time for long-term…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

1 Marijuana Stock I’d Buy Over Aurora Cannabis

Explore a promising marijuana stock that outshines Aurora Cannabis. Unveil the investment opportunity to boost your cannabis portfolio.

Read more »